The age-related macular degeneration clinical trial analysis report delivers important insights into ongoing research of 100+ pipeline age-related macular degeneration drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

New York, USA, June 18, 2026 (GLOBE NEWSWIRE) -- Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight’s 'Age-related Macular Degeneration Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for age-related macular degeneration across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the age-related macular degeneration domain.

Age-related Macular Degeneration Clinical Trial Analysis Summary

DelveInsight’s age-related macular degeneration pipeline report depicts a robust space with 90+ active players working to develop 100+ pipeline age-related macular degeneration drugs.
Key age-related macular degeneration companies, such as Stealth BioTherapeutics, 4D Molecular Therapeutics, Merck, Sanofi, Evergreen Therapeutics, ONL Therapeutics, Caregen Co., Ltd., HuidaGene Therapeutics, SCAI Therapeutics, PulseSight Therapeutics, Frontera Therapeutics, Beijing Anlong Biopharmaceutical Co., Ltd., Chengdu Origen Biotechnology Co., Ltd., Benobio Co., Ltd., Skyline Therapeutics, Innostellar Biotherapeutics Co., Ltd, Kriya Therapeutics, Inc., Elisigen, Inc., Eli Lilly and Company, EyePoint Pharmaceuticals, Inc., Ocugen, Ray Therapeutics, Beacon Therapeutics, Regenxbio, Surrozen, and others, are evaluating new age-related macular degeneration drugs to improve the treatment landscape.
Promising pipeline age-related macular degeneration therapies, such as Elamipretide, 4D-150, MK-8748, SAR402663, EG-301, Xelafaslatide, CG-P5, HG202, SCAI 010, PST-611, FT-003, AL-001, KH658, BBC1501, SKG0106, LX102, KRIYA-825, NG101, Ixoberogene Soroparvovec, EYP-1901, OCU410, RTX-021, BTX-001, RGX-314, SZN-8141, and others, are in different phases of age-related macular degeneration clinical trials.
Approximately 15+ age-related macular degeneration drugs are in the late stages of development.
Notable MoAs in age-related macular degeneration clinical trials include Mitochondrial cardiolipin stabilization, Vascular endothelial growth factors expression inhibitors, Tie2 Agonist/VEGF Inhibitor, FLT1 protein replacements, Gene transference, Functional inhibitor of acid sphingomyelinase (ASM), Fas receptor inhibitor, RNA modulators, Vascular endothelial growth factor A expression inhibitors, Multi-target TKI inhibition, and others.

Request a sample and discover the recent advances in age-related macular degeneration drug development @ https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-pipeline-insight

What is Age-related Macular Degeneration?

Age-related macular degeneration (AMD) is a progressive eye condition that primarily affects older adults and leads to the deterioration of the macula, the central part of the retina responsible for sharp, detailed vision. As the disease advances, it can cause blurred or distorted central vision, making everyday tasks such as reading, recognizing faces, and driving increasingly difficult, while peripheral vision typically remains intact. AMD is broadly classified into two types: dry, which is more common and progresses gradually due to the accumulation of drusen deposits, and wet, a less common but more severe form characterized by abnormal blood vessel growth and leakage beneath the retina. Risk factors include aging, genetic predisposition, smoking, and lifestyle factors, and although there is no cure, early detection and appropriate management can help slow disease progression and preserve vision.

Find out more about age-related macular degeneration drug development @ Age-related Macular Degeneration Treatment

A snapshot of the Pipeline Age-related Macular Degeneration Drugs mentioned in the report:

Drugs	Company	Phase	MoA	RoA
Elamipretide	Stealth BioTherapeutics	III	Mitochondrial cardiolipin stabilization	SC
4D-150	4D Molecular Therapeutics	III	Vascular endothelial growth factors expression inhibitors	Intravitreal
MK-8748	Merck	II/III	Tie2 Agonist/VEGF Inhibitor	Intravitreal
SAR402663	Sanofi	II	FLT1 protein replacements; Gene transference	Intravitreal
EG-301	Evergreen Therapeutics	II	Functional inhibitor of acid sphingomyelinase (ASM)	Oral
Xelafaslatide	ONL Therapeutics	II	Fas receptor inhibitor	Intravitreal
CG-P5	Caregen Co., Ltd.	I	Vascular endothelial growth factors expression inhibitors	Topical
HG202	HuidaGene Therapeutics	I	RNA modulators; Vascular endothelial growth factor A expression inhibitors	Subretinal
SCAI 010	SCAI Therapeutics	Preclinical	Multi-target TKI inhibition	Topical

Learn more about the emerging age-related macular degeneration therapies @ Age-related Macular Degeneration Clinical Trials

As per Stuti Mahajan, consulting manager at DelveInsight, the AMD market is driven by the growing elderly population, increasing disease prevalence, and rising demand for durable vision-preserving therapies with reduced injection burden. At the same time, next-generation biologics, gene therapies, complement inhibitors, and sustained-delivery technologies are advancing the AMD landscape beyond traditional anti-VEGF treatment approaches.

Recent Developments in Age-related Macular Degeneration Treatment Space

In April 2026, Merck announced the initiation of a Pivotal Phase IIb/III trial evaluating MK-8748 (also known as Tiespectus, EYE201), a novel investigational bispecific antibody that directly activates Tie2 signaling and inhibits vascular endothelial growth factor (VEGF), for the treatment of neovascular (wet) age-related macular degeneration (NVAMD).
In March 2026, ONL Therapeutics, Inc. announced that the first European participant has been randomized in the company's Phase II GALAXY trial. GALAXY is a global Phase II clinical trial designed to evaluate the efficacy and safety of xelafaslatide (formerly ONL1204) in patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).
In February 2026, 4D Molecular Therapeutics announced enrollment completion for 4FRONT-1, the first Phase III clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).
In November 2025, 4D Molecular Therapeutics announced positive interim 1.5- to 3.5-year data from the Phase I/II PRISM clinical trial evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).
In October 2025, Regenxbio announced the completion of Phase II pivotal trials (ATMOSPHERE and ASCENT) evaluating surabgene lomparvovec (RGX-314) for the treatment of wet-AMD, with topline data expected in 2026.
In October 2025, Eli Lilly and Company and Adverum Biotechnologies, Inc. announced a definitive agreement for Lilly to acquire Adverum Biotechnologies, Inc., including its lead product candidate, Ixo-vec.
In September 2025, the US FDA granted fast-track designation to SAR402663, an investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration (AMD).
In July 2025, 4D Molecular Therapeutics announced the acceleration of the 4D-150 4FRONT Phase III program in wet age-related macular degeneration (wet AMD).
In March 2025, Stealth BioTherapeutics Inc. announced that it has achieved its 50 percent enrollment target in the global Phase III ReNEW study (NCT06373731) of elamipretide in patients with dry age-related macular degeneration (dry AMD).
In March 2025, Adverum Biotechnologies initiated its ARTEMIS Phase III study to evaluate the efficacy and safety of ixoberogene soroparvovec (Ixo-vec) for patients with neovascular (wet) age-related macular degeneration (AMD).

Scope of the Age-related Macular Degeneration Pipeline Report

Coverage: Global
Age-related Macular Degeneration Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Age-related Macular Degeneration Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Age-related Macular Degeneration Therapeutics Assessment By Route of Administration: Intravenous, Subcutaneous, Oral, Intramuscular
Age-related Macular Degeneration Therapeutics Assessment By Molecule Type: Monoclonal antibody, Small molecule, Peptide
Age-related Macular Degeneration Therapeutics Assessment By Mechanism of Action: Mitochondrial cardiolipin stabilization, Vascular endothelial growth factors expression inhibitors, Tie2 Agonist/VEGF Inhibitor, FLT1 protein replacements, Gene transference, Functional inhibitor of acid sphingomyelinase (ASM), Fas receptor inhibitor, RNA modulators, Vascular endothelial growth factor A expression inhibitors, Multi-target TKI inhibition, and others
Key Age-related Macular Degeneration Companies: Stealth BioTherapeutics, 4D Molecular Therapeutics, Merck, Sanofi, Evergreen Therapeutics, ONL Therapeutics, Caregen Co., Ltd., HuidaGene Therapeutics, SCAI Therapeutics, PulseSight Therapeutics, Frontera Therapeutics, Beijing Anlong Biopharmaceutical Co., Ltd., Chengdu Origen Biotechnology Co., Ltd., Benobio Co., Ltd., Skyline Therapeutics, Innostellar Biotherapeutics Co.,Ltd, Kriya Therapeutics, Inc., Elisigen, Inc., Eli Lilly and Company, EyePoint Pharmaceuticals, Inc., Ocugen, Ray Therapeutics, Beacon Therapeutics, Regenxbio, Surrozen and others.
Key Age-related Macular Degeneration Pipeline Therapies: Elamipretide, 4D-150, MK-8748, SAR402663, EG-301, Xelafaslatide, CG-P5, HG202, SCAI 010, PST-611, FT-003, AL-001, KH658, BBC1501, SKG0106, LX102, KRIYA-825, NG101, Ixoberogene Soroparvovec, EYP-1901, OCU410, RTX-021, BTX-001, RGX-314, SZN-8141 and others.

Dive deep into rich insights for new age-related macular degeneration treatments, visit @ Age-related Macular Degeneration Drugs

Table of Contents

1.	Age-related Macular Degeneration Pipeline Report Introduction
2.	Age-related Macular Degeneration Pipeline Report Executive Summary
3.	Age-related Macular Degeneration Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Age-related Macular Degeneration Clinical Trial Therapeutics
6.	Age-related Macular Degeneration Pipeline: Late-Stage Products (Pre-registration)
7.	Age-related Macular Degeneration Pipeline: Late-Stage Products (Phase III)
8.	Age-related Macular Degeneration Pipeline: Mid-Stage Products (Phase II)
9.	Age-related Macular Degeneration Pipeline: Early-Stage Products (Phase I)
10.	Age-related Macular Degeneration Pipeline Therapeutics Assessment
11.	Inactive Products in the Age-related Macular Degeneration Pipeline
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Companies
14.	Key Products in the Age-related Macular Degeneration Pipeline
15.	Unmet Needs
16.	Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

For further information on the age-related macular degeneration cure research, reach out @ Medication for Age-related Macular Degeneration Treatment

Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AMD companies, including Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Evergreen Therapeutics, Alkeus Pharmaceuticals, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics, and others.

Dry Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dry AMD companies including Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics (CellCure Neurosciences), Roche, Cognition Therapeutics, Stealth BioTherapeutics, Annexon Biosciences, and others.

Wet Age-related Macular Degeneration Market Insight, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key wet AMD companies, including Adverum Biotechnologies, Regenxbio, AbbVie, Ocugenix, Alkahest, Ribomic USA, 4D Molecular Therapeutics, AffaMed Therapeutics, Clearside Biomedical, Caregen, Elisigen, NexThera, Ashvattha Therapeutics, Avirmax Biopharma, Roche, Novartis, Regeneron Pharmaceuticals, Bayer, and others.

Wet AMD Clinical Trial Analysis

Wet AMD Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key wet AMD companies, including Sylentis, Molecular Partners, Sam Chun Dang Pharm, Generium, Alvotech, Adverum Biotechnologies, EyePoint Pharmaceuticals, 4D Molecular Therapeutics, OliX Pharmaceuticals, Kyowa Kirin, Exonate, and others.

Geographic Atrophy Market

Geographic Atrophy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key geographic atrophy companies, including Apellis Pharmaceuticals, Iveric Bio (formerly Ophthotech Corporation), Alkeus Pharmaceuticals, Hemera Biosciences, Allegro Ophthalmics, Stealth BioTherapeutics, Regenerative Patch Technologies, Novartis, Roche, Ionis Pharmaceuticals, CellCure Neurosciences (a subsidiary of Lineage Cell Therapeutics), and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679